Summit Therapeutics (SMMT) Tops Q4 EPS by 19c

Summit Therapeutics (NASDAQ: SMMT) reported Q4 EPS of (GBP0.07), GBP0.19 better than the analyst estimate of (GBP0.26).

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• UBS Starts Allwyn AG (ALWN:GA) at Neutral
• JPMorgan Reiterates Underweight Rating on DSM-Firmenich AG (DSFIR:NA), Places on Negative CW